Signant Health (formerly CRF Health and Bracket) will provide expert insights at the forthcoming DIA Global Annual Meeting in San Diego, CA June 23-27, 2019. Signant will have a presence at DIA as the company celebrates its new brand launch with customers.
“Although the name Signant Health is new, our expert technology and scientific teams have partnered with sponsors and CROs for over 20 years,” said Mike Nolte, CEO of Signant Health. “Each year, DIA encourages important conversations about advancing research, and our contribution to that dialogue will be a ruthless focus on the patient experience. Our strategy and our team are focused on building solutions from the patient out, delivering speed, efficiency and increased data integrity. That simplicity and clarity extends the reach of drug development, reduces investment and improves data integrity as sponsors and CROs bring life-changing therapies to our families and communities around the world.”
Signant Health sessions at DIA 2019, chaired and presented by Bill Byrom, PhD, include:
The Face is a Mirror of the Mind: The Potential of Expression Detection for New Clinical Outcome Measures exploring new insights and potential new clinical endpoints generated via remote video diaries and video interactions with patients. Discussing expression detection and voice acoustics measures, the session will explore additional insights to be gained to assess patient health status and understand more about the effects of treatment. Monday, June 24 - 11:00am
How eConsent will Support Increased Insights and Future Enhancement of Informed Consent Content and Processes reviewing additional insights and value that can be extracted from the metadata associated with eConsent implementations – including richer learnings about reasons participants decline to participate, areas of consenting information that generate the most questions or misunderstandings –to continually improve information delivered and processes around consenting implementation. Tuesday, June 25 - 8:00am
Using Mobile Sensors in Clinical Trials and Evidentiary Considerations for Electronic Submissions shares insights on the current work of the DIA Study Endpoint Community Wearables Group, specifically related to three areas: how to select a clinical endpoint derived from mobile sensor data; how to select a fit for purpose device and provide evidence to support its use; considerations regarding the positioning of endpoints derived from mobile sensor data alongside other clinical endpoints in the endpoint hierarchy. Tuesday, June 25 - 4:15pm
eCOA and Connected Devices for Supporting Oncology Patients in Clinical Trials will be chaired and presented by Brad Sanderson, illustrating past challenges and future opportunities for the use of electronic patient-reported outcomes and wearable technology in the Oncology therapy areas. Tuesday, June 25 - 10:30am
Additionally, Signant Health’s team of scientists, clinicians and subject matter experts will be on-hand at the company’s booth to discuss in greater detail clinical research technology and services, to ensure Sponsors and CROs achieve the highest quality endpoint data across a range of therapeutic areas, including oncology, immunology, CNS and rare diseases.